Anxiety symptoms
Anxiolytic effects are Selank's primary clinical research theme.
WHAT THE RESEARCH SAYS
Small studies comparing Selank with medazepam or phenazepam reported symptom improvements.
Evidence so farEarly human evidence
ANXIETY & STRESS-RESPONSE RESEARCH
Selank
Selank is best known for interest around calm, anxiety, stress resilience and cognitive function, supported by early regional human research.
Anxiety researchStress responseCognition
Small regional clinical studies; broader confirmation neededComparative and clinical studies report anxiolytic signals, but the literature is relatively small, largely Russian-language and not equivalent to a large modern placebo-controlled programme.
WHY PEOPLE ARE INTERESTED
Why are people interested in Selank?
Selank is often framed as a calming peptide without the cognitive dulling associated with some medicines. That is an attractive hypothesis, but the evidence base remains limited.
Start with the big picture
These cards show what Selank is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
AT A GLANCESelank
Anxiety researchStress responseCognition
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Cognition under stress
People are interested in calmness without sedation or reduced performance.
WHAT THE RESEARCH SAYS
Clinical reports describe mild nootropic effects, but modern objective cognitive trials are limited.
Evidence so farLimited human evidence
Stress resilience
Rather than simply causing sedation, much of the interest is about coping with stress while remaining mentally functional and alert.
WHAT THE RESEARCH SAYS
Human symptom studies and preclinical stress models offer preliminary support.
Evidence so farDeveloping evidence
Immune-neural signalling
As a tuftsin analogue, Selank is also studied for immunomodulatory effects.
WHAT THE RESEARCH SAYS
Small studies report cytokine changes; clinical significance is uncertain.
Evidence so farMechanistic + early human evidence
Interest first. Evidence next.We start with why people are talking about Selank, then show what the research actually supports so you can see the full picture.
HOW TO READ THE RESEARCH STORY
TUFTSIN ANALOGUEA calm-focus hypothesis with an early human signal
Selank's strongest clinical theme is anxiety—not generic productivity. Small comparative studies are encouraging enough to follow, but not strong enough to settle efficacy or long-term use.
01Tuftsin analogue
Immune-neural origin and signalling interest
→02Intranasal exposure
The route used in regional clinical work
→03Anxiety signal
Small comparisons with established medicines
→04Modern validation
Placebo-controlled replication still needed
WHAT RESEARCH IS EXPLORING
A tuftsin-derived peptide studied around anxiety and calm cognition
Selank has small comparative human studies rather than a purely animal evidence base. The next scientific step is modern blinded replication with transparent nasal delivery, patient-important outcomes and longer follow-up.
01
Anxiety outcomes
Small regional studies compared intranasal Selank with established anxiolytic medicines.
02
Calm cognition
Reports of antiasthenic or mild nootropic effects motivate interest in performance under stress.
03
Immune–neural biology
Its tuftsin-derived structure creates a distinct immunomodulatory and neurochemical research theme.
04
Replication boundary
Large placebo-controlled trials, detailed delivery data and long-term safety remain absent.
RESEARCH LANDSCAPEAnxiety · calm cognition · immune–neural signalling
Anxiety studiesStress responseCognitionTuftsin analogue
Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableSelank in generalized anxiety disorder and neurasthenia ↗
62 patients; Selank (30) compared with medazepam (32)
Intranasal Selank; oral comparator14 days
Anxiolytic effects were reported as similar between groups, with antiasthenic and psychostimulant effects also described for Selank.
The small Russian-language study and limited reporting prevent the confidence of a modern large placebo-controlled programme.
Selank compared with phenazepam in anxiety disorders ↗
60 patients with phobic-anxiety and somatoform disorders
Intranasal Selank; oral comparator
The report described anxiolytic and mild nootropic effects with a tolerability comparison.
It was not a large internationally replicated placebo-controlled programme.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
Several small clinical and comparative studies report anxiety-related effects.
✓
Clinical efficacyLimited
2/5 evidence depth
Lack of large blinded placebo-controlled replication limits efficacy certainty.
◇
Safety evidenceLimited
2/5 evidence depth
Short clinical courses provide some tolerability data; long-term and combination safety remain uncertain.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Animal and molecular research supports anxiolytic and immune-neural mechanisms.
HOW TO READ THESE SCORESDeveloping preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPESelankMechanism → translation → human outcome
Small anxiety studies report a positive signal
Stress, neurotransmission and immune-neural research
Blinded replication, dose detail and long-term safety
What this snapshot does—and does not—show
It separates biological plausibility from demonstrated benefit. A compelling mechanism can justify better trials; it cannot substitute for them.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
PEOPLE & EXPERIENCE
Why people are exploring Selank
Calmer thinking, anxiety relief and resilience under stress—mapped against small comparative human studies and mechanistic research.
Community goals · early human signal · replication gapWhy this matters
Users explore Selank for anxiety reduction, social ease and calm focus. Small clinical reports make this more than a purely preclinical story, but evidence quality and replication remain limited.
Frequently discussedCalmer without sedation
↓02Frequently discussedSocial confidence and stress control
↓03Frequently discussedCalm focus
↓04Frequently discussedShort intranasal courses
↓◎WHAT PEOPLE REPORTReal-world interest
+Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
⌁WHAT RESEARCH ADDSScientific context
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
01Frequently discussed
Frequently discussedPositive interest with important uncertainty
Calmer without sedation
This is the most repeated positive theme in community discussion.
HUMAN EVIDENCE
Comparative studies reported anxiolytic effects and reasonable tolerability, but were small.
MECHANISTIC / PRECLINICAL
Animal anxiety and neurotransmission studies support a non-benzodiazepine mechanism.
WHERE IT STANDS TODAY
Encouraging early human signal requiring better controlled replication.
02Frequently discussed
Frequently discussedPositive interest with important uncertainty
Social confidence and stress control
People often describe less anticipatory anxiety or improved social comfort.
HUMAN EVIDENCE
Specific social-anxiety outcomes have not been established in large trials.
MECHANISTIC / PRECLINICAL
Stress-response research provides a plausible basis.
WHERE IT STANDS TODAY
Community detail is more specific than the published evidence.
03Frequently discussed
Frequently discussedPositive interest with important uncertainty
Calm focus
Selank is commonly paired with cognitive-performance goals.
HUMAN EVIDENCE
Mild nootropic effects were reported in small studies; objective evidence remains limited.
MECHANISTIC / PRECLINICAL
Memory and neurotrophic mechanisms are explored in animal work.
WHERE IT STANDS TODAY
Potentially interesting, but not a proven cognitive enhancer.
04Frequently discussed
Frequently discussedPositive interest with important uncertainty
Short intranasal courses
Community descriptions often mirror the brief course structure seen in regional clinical literature, but use different concentrations and spray devices.
HUMAN EVIDENCE
Small studies support intranasal exposure over short treatment windows; their abstracts do not provide enough product-delivery detail to validate a retail spray conversion.
MECHANISTIC / PRECLINICAL
Animal dose and route research cannot establish the amount delivered by a human nasal product.
WHERE IT STANDS TODAY
A recognisable route and course pattern, with major dose-accuracy and replication gaps.
Experience can start the question. Research has to test it.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toSelank, while the available studies show how far that question has already been answered.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
Research dose ≠ recommendation. A dose used in a study describes that study only and does not establish an appropriate dose for an individual outside the research setting.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA brief intranasal course with a review point
The route and short-course idea resemble regional clinical research, but the amount below is community-described and product delivery varies.
1Days 1–3
250 mcg / dayAnecdotal intranasal starting amount
2Days 4–7
250–500 mcg / daySome descriptions divide daily use
3Days 8–14
Up to 750 mcg / dayUpper end of recurring community descriptions
4After course
Pause & reviewNo validated maintenance interval
What people commonly discuss250–750 mcg/day intranasally for 10–14 days, with divided use appearing in some descriptions.
What remains unvalidatedThe commonly shared amount, spray conversion, escalation and break pattern have not been validated in a modern dose-finding trial.
ROUTE & DELIVERYConcentration and pump volume decide delivery
Two products can deliver very different micrograms per spray. Study route does not validate an unlabelled or inaccurately compounded nasal product.
PROFESSIONAL SOURCE CONTEXT
Selank GAD comparative study · PubMed ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Clinical publications describe short intranasal courses, but no internationally validated Selank protocol exists for general anxiety or wellness use.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · regional clinical extrapolationWhat people commonly discuss
STARTING APPROACHES
Community descriptions often begin around 250 mcg intranasally per day; 500–750 mcg/day in divided use is also discussed.
DURATION / CYCLES
Short 10–14-day courses are common, while some people describe occasional use around stressful periods.
MAINTENANCE DISCUSSION
No validated continuous-use, cycling, tolerance-prevention or break schedule exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Selank
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDSelank
→
OFTEN EXPLORED WITHSelank + Semax
Selank + Semax
→
OFTEN EXPLORED WITHSelank + psychological therapy
Selank + Evidence-based therapy
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
SSELANK IS USUALLY DISCUSSED AROUNDAnxiety, stress response and calm cognition
＋Small human studies motivate interest, while modern placebo-controlled replication remains the central gap.
PTHE PAIRED APPROACH MAY ADDGreater activation or evidence-based psychological treatment
Semax adds a more activating research story; therapy adds an established behavioural approach, not a proven peptide synergy.
＋
OFTEN EXPLORED WITH
Explore →＋Selank + Semax
Selank + SemaxWHY IT IS EXPLOREDExplored around calm focus and stress-resilient cognition.
No controlled human evidence for the combination.OFTEN EXPLORED WITH
Explore →Selank + psychological therapy
Selank + Evidence-based therapyWHY IT IS EXPLOREDCommunities discuss combining symptom relief with behavioural treatment.
Selank has not been shown to enhance therapy outcomes and should not replace established care.01Keep the goal measurable
Anxiety relief, social comfort and productivity require different outcomes and follow-up.
02Protect established care
A peptide pairing should not trigger abrupt changes to prescribed psychiatric treatment.
03Watch the combined state
Sleep loss, agitation or mood change may matter more than the rationale for a stack.
Safety context
SAFETY & UNCERTAINTY
Short-term tolerability is better studied than long-term use
01ENCOURAGING CONTEXTSmall human anxiety studies exist
Short comparative courses provide a preliminary tolerability and efficacy signal beyond preclinical work alone.
02THE IMPORTANT BOUNDARYSmall comparisons are not definitive treatment evidence
Limited blinding, regional reporting and absent large replication leave the size and reliability of benefit uncertain.
03WHAT REMAINS UNKNOWNLong-term use and psychiatric-medication interactions
Repeated courses, dependency expectations, mood effects and combination safety have not been established.
What the current evidence saysSmall clinical studies provide some reassurance for short courses, but long-term neuropsychiatric effects, interactions, product concentration and combined use with psychiatric medicines are not well characterised.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Stopping prescribed anxiety treatment can cause harm; changes should be discussed with the treating clinician.
A spray count without delivered micrograms is not a reproducible dose.
Severe agitation, suicidal thinking, panic escalation or marked mood change requires urgent professional support.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
4 sourcesSources used on this profile
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Selank is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.